TNDM grants 20,242 restricted stock units to company director

Rhea-AI Filing Summary

Tandem Diabetes Care, Inc. (TNDM) reported an equity award to one of its directors on a Form 4. The director received 20,242 restricted stock units (RSUs) on November 7, 2025 under the company’s 2023 Long-Term Incentive Plan.

Each RSU represents a right to receive either one share of Tandem’s common stock or cash, at the company’s discretion, subject to the plan’s terms. The RSUs vest as to 33% of the total award on November 15, 2026, with the remaining units vesting in two equal annual installments after that date, contingent on the applicable conditions being met.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Beaver Sandra

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	20,242	$0.00	--

Holdings After Transaction: Restricted Stock Unit — 20,242 shares (Direct)

Footnotes (1)

1. Awarded on November 7, 2025 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 11/15/2026, and the remaining shares shall vest in two (2) equal annual installments thereafter.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Beaver Sandra

(Last) (First) (Middle)

12400 HIGH BLUFF DRIVE

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TANDEM DIABETES CARE INC [ TNDM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit(1)	(2)	11/07/2025		A		20,242		(3)	(3)	Common Stock	20,242	$0	20,242	D

Explanation of Responses:

1. Awarded on November 7, 2025 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

2. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

3. RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 11/15/2026, and the remaining shares shall vest in two (2) equal annual installments thereafter.

Remarks:

	/s/ Shannon M. Hansen, Attorney-in-Fact for Sandra Beaver	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Tandem Diabetes Care (TNDM) disclose in this Form 4?

The filing reports that a director of Tandem Diabetes Care, Inc. (TNDM) was granted 20,242 restricted stock units (RSUs) on November 7, 2025 under the company’s 2023 Long-Term Incentive Plan.

How many Tandem Diabetes Care (TNDM) RSUs were granted to the director?

The director was granted 20,242 RSUs, each representing a contingent right to receive one share of Tandem Diabetes Care common stock or cash in lieu, at the company’s discretion.

What is the vesting schedule for the 20,242 RSUs reported by TNDM?

The RSUs vest as to 33% of the total award on November 15, 2026, and the remaining RSUs vest in two equal annual installments thereafter, subject to the plan terms.

Under which plan were these Tandem Diabetes Care (TNDM) RSUs granted?

The RSUs were granted under the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, pursuant to applicable award agreements.

Does the Tandem Diabetes Care (TNDM) director receive shares or cash from these RSUs?

Each RSU gives the director a contingent right to receive either one share of Tandem Diabetes Care common stock or cash in lieu, at the company’s discretion, in line with the 2023 plan.

Is this TNDM Form 4 filed for a single reporting person?

Yes. The Form 4 is indicated as filed by one reporting person, who serves as a director of Tandem Diabetes Care, Inc.